Regis Technologies Hires Additional Scientists

Regis Technologies Hires Additional Scientists
Former deCODE NMR and development and production staff join Regis

Morton Grove, Illinois - December 15, 2009.  Regis Technologies, Inc., a leading provider of cGMP and non-GMP synthesis and separations services for active pharmaceutical ingredients that help expedite drugs to market, announced today that it has expanded its scientific staff with the addition of four scientists formerly employed by deCODE genetics Inc., which filed this month for Chapter 11 protection in U.S. Bankruptcy Court.

Joining Regis as  a lead NMR specialist is Nelson Zhao, PhD Biochemistry. Igor Likhotvorik, PhD Chemistry, Sied Zegar, BS Chemistry, and Dragan Ristic, BS Engineering, all of deCODE's development and production staff, are also joining Regis's staff.

"Regis Technologies has always believed that our employees are our core strength, and to be able to add these scientists to our staff is a tremendous opportunity for us and for our customers," said Louis Glunz IV, president of Regis. "These hires fit strategically with our plan for growth and enhanced customer services."

About Regis Technologies, Inc.
Regis Technologies, a privately held company founded in 1956, helps biotechnology and pharmaceutical companies expedite their drugs to market. Our cGMP and non-GMP synthesis and separations services advance active pharmaceutical ingredients (APIs) and intermediates from initial process development and scale-up to final validation and commercial manufacturing. We are a leading manufacturer of chromatography products and services, especially those with a chiral emphasis, and our SFC separation services offers analysis and purification of chiral separations. Additionally, we manufacture high purity, fine organic chemicals. Our facility, now 51,000-square feet, has been fully GMP compliant since 1993. For more information, visit www.registech.com.

Contacts:
Sean F. Bradley
Director of Business Development
847-583-7631.
[email protected]
Debra Harrsch
Brandwidth Solutions LLC
215-997-8575
[email protected]

Suggested Articles

Half of patients in an early trial of Allogene's off-the-shelf CAR-T cells for lymphoma who received a higher dose of its antibody ALLO-647 responded.

Takeda is tossing out a Shire pipeline med after it couldn't find a buyer.

Ipsen's new hire arrives at a company reeling from a torrent six months that have crushed hopes for its $1 billion bet on a rare disease drug.